Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

August 14, 2019August 14, 2019

Variations in Certain Immune Genes May Help Predict Risk for Developing FVIII Inhibitors in Hemophilia A

News

Genetic variations in certain immune-related genes, namely the HLA and IL-10 genes, are linked with an increased risk for developing inhibitors against factor VIII replacement therapies in patients with ... Read more

August 5, 2019August 5, 2019

Parent’s Sense of Burden Higher When Child Overweight and Has Inhibitors, Study Finds

News

The presence of inhibitors and excessive body weight increase the sense of disease burden felt by parents of children with moderate to severe hemophilia, a study reports. The study ... Read more

July 19, 2019July 19, 2019

Two-stage Gene Therapy for Hemophilia A Shows Promising Results in Mice, Researchers Say

News

Casebia’s two-stage gene therapy approach was successful in delivering the human gene coding for clotting factor VIII (FVIII) in a mouse model of hemophilia A, leading to stable and ... Read more

July 8, 2019July 8, 2019

Vaccination of Hemophilia Patients Varies in Germany and Should Be Reassessed to Minimize Fear, Survey Suggests

News

Recommendations for vaccination practices for patients with hemophilia should be reassessed in an effort to minimize fear and emphasize the importance of vaccination to prevent infections, suggests a survey ... Read more

July 1, 2019July 1, 2019

Higher FVIII Blood Levels Seen and Better Maintained with Jivi Than Eloctate, Phase 1 Study in Severe Hemophilia A Finds

News

Bayer’s Jivi, an FVIII replacement therapy for hemophilia A, has a longer half-life and a slower clearance from blood circulation than Eloctate, and may protect against bleeding for longer periods, ... Read more

May 31, 2019May 31, 2019

BioMarin’s Gene Therapy for Severe Hemophilia Yields Sustained Benefit, Data Show

News

BioMarin Pharmaceutical’s investigative gene therapy, called valoctocogene roxaparvovec, is capable of sustained control of bleeding rate requiring factor VIII infusions by at least 92% in adults with severe hemophilia A, ... Read more

May 24, 2019May 24, 2019

Web-Based Calculator Helps Physicians to Finetune Dosage of Hemlibra for Hemophilia A Patients

News

BrightInsight has launched a web-based dosing calculator to help physicians select the correct loading and maintenance dose of the treatment Hemlibra according to the body measurements of their patients ... Read more

May 17, 2019May 17, 2019

Candidate Cell Therapy Controls Bleeding in Mouse Model of Hemophilia A

News

Sigilon Therapeutics’ candidate cell therapy for hemophilia A, called SIG-001, delivers sustained production of factor VIII for over six months and corrects bleeding in a hemophilia A mouse model. ... Read more

May 16, 2019May 20, 2019

ASC Therapeutics Licenses Tech from Expression Therapeutics to Advance Gene Therapies

News

ASC Therapeutics has gotten exclusive rights to Expression Therapeutics‘ technology to develop liver-targeting hemophilia A gene therapies. “We have a common mission with Expression Therapeutics — to develop novel ... Read more

May 13, 2019May 13, 2019

New Hemophilia Database Tracks and Updates Patient Clinical Data in Real Time, Trio Health Announces

News

Trio Health has launched a novel database with real-time clinical data of patients with hemophilia which combines information from medical doctors and pharmacies. The main aim of the database ... Read more

Pin It on Pinterest